- Report
- June 2026
- 195 Pages
Global
From €3213EUR$3,545USD£2,738GBP
€3571EUR$3,939USD£3,042GBP
- Report
- June 2026
- 183 Pages
Global
From €3213EUR$3,545USD£2,738GBP
€3571EUR$3,939USD£3,042GBP
- Report
- June 2026
- 188 Pages
Global
From €3213EUR$3,545USD£2,738GBP
€3571EUR$3,939USD£3,042GBP
- Report
- July 2025
- 350 Pages
Global
From €4486EUR$4,949USD£3,822GBP
- Report
- November 2019
- 271 Pages
Global
From €2719EUR$3,000USD£2,317GBP
Birth Asphyxia is a condition in Pediatrics where a newborn baby does not receive enough oxygen before, during, or after birth. It is a leading cause of death and disability in newborns, and can lead to long-term neurological and developmental problems. It is caused by a variety of factors, including umbilical cord problems, placental problems, and maternal health issues. Treatment for Birth Asphyxia includes oxygen therapy, cooling therapy, and medications.
There are a number of companies in the Birth Asphyxia market, including Philips Healthcare, Masimo Corporation, and Covidien. Philips Healthcare provides a range of products and services for neonatal care, including monitoring systems and oxygen therapy. Masimo Corporation offers a range of monitoring and diagnostic products for neonatal care, including pulse oximetry and capnography. Covidien provides a range of products and services for neonatal care, including oxygen therapy and cooling therapy. Show Less Read more